profit from every ₹100 of sales.
₹0₹100
Caplin Point Laboratories
₹2,377.60-0.45% today
+21.6% in 1 year
1-year low ₹1,505.151-year high ₹2,865.80
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹28.18 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Caplin Point Laboratories sold, what it kept, and what it did with the cash.
Sales went from ₹14.5 billion in 2023 to ₹21.9 billion in 2026, with ₹6.41 billion of profit last year.
SalesProfit
Caplin Point Laboratories handed back 17% of the cash it generated last year.
₹456M
Free cash flow 2026₹2.8B
Bought back its own shares–
Paid as dividends₹456M
Cash vs. debt₹942M vs. ₹46M
Caplin Point Laboratories vs. similar companies
Caplin Point Laboratories grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Caplin Point Laboratories | 28.2× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Caplin Point Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 14,538 | 16,796 | 19,375 | 21,872 | |
| 7,846 | 9,502 | 11,666 | 13,215 | |
| 3,984 | 4,980 | 5,810 | 6,881 | |
| 4,971 | 6,187 | 7,434 | 8,764 | |
| 3,763 | 4,571 | 5,363 | 6,412 | |
| 49.18 | 59.90 | 70.25 | 84.11 | |
| 54.0% | 56.6% | 60.2% | 60.4% | |
| 27.4% | 29.7% | 30.0% | 31.5% | |
| 25.9% | 27.2% | 27.7% | 29.3% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 21,914 | 26,981 | 32,090 | 40,455 |
| Cash | 4,845 | 5,458 | 1,995 | 942 |
| Total debt | 55 | 20 | 50 | 46 |
| Total liabilities | 2,841 | 3,513 | 3,226 | 4,147 |
| 18,805 | 23,157 | 28,505 | 35,864 | |
| 77 | 76 | 76 | 76 | |
| 18.9% | 19.3% | 18.7% | 17.7% | |
| 20.0% | 19.7% | 18.8% | 17.9% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,714 | 3,184 | 4,324 | 5,232 | |
| 1,935 | 1,458 | 1,915 | 2,481 | |
| 779 | 1,726 | 2,409 | 2,751 | |
| Dividends paid | 303 | 342 | 380 | 456 |
| – | – | – | – | |
| 52 | 9 | 94 | -13 |
Valuation
- 28.2×
- –
- 1.44
- 4.9×
- 8.3×
- 65.7×
- 20.5×
- 1.5%
- 3.5%
- 0.3%
Profitability
- 60.4%
- 31.5%
- 29.3%
- –
- 16.8%
- 17.7%
- –
- –
- –
- –
Growth
- +14.6%
- +19.6%
- –
- –
- −0.1%
Financial health
- -0.1×
- 0.00
- –
- 923.7×
- 6.70
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 13%of 946
Top 9%of 871
Top 49%of 563
Top 40%of 867
Top 47%of 986
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
7.1% of its profit
Room to growStretchedMore than it earns: 16.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
62Pass
Philip Fisher
83Pass
Peter Lynch
76Pass
Joel Greenblatt
33No pass
Charlie Munger
75Pass
Terry Smith
63Pass
Questions about Caplin Point Laboratories
Is Caplin Point Laboratories a good stock to buy?
A strong, very profitable business at a fair price. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Caplin Point Laboratories AI analysis
What does Caplin Point Laboratories do?
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. It is in Drug Manufacturers - Specialty & Generic, based in Chennai, India.
Does Caplin Point Laboratories pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 7% of its yearly profit. In 2026 it paid out ₹456 million in dividends.
Is Caplin Point Laboratories stock halal?
Yes. Caplin Point Laboratories passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Caplin Point Laboratories stock done over the past year?
Up 21.6% over the past twelve months, to ₹2,377.60. It traded between ₹1,505.15 and ₹2,865.80 and is 17.0% below its high.
Who are Caplin Point Laboratories's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Caplin Point Laboratories's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.